An important international test suggests that a combination of caglintide and semaglutide helps adults with obesity to achieve more dramatic weight loss and better metabolic health than current single-drug remedies.
tests: Coadministerhed Cagrilintide and semaglutide in adults with overweight or obesityImage Credit: Alons / Shutterskk
In a recent study published in New England Journal of MedicineA group of researchers evaluated the effectiveness of a joint diet of caglintide and Malevolent Its protection for adults with reducing body weight and obesity without diabetes.
background
About half of adults worldwide now live with additional body fat, it is estimated to climb up to 54% by 2035, and it runs type 2 diabetes, hypertension, dyslipidmia, osteoarthritis and mood disorders. Long-term weight-management drugs work best when healthy food habits and regular physical activity.
Semglutide mimic Glucagon-The peptide 1 (GLP-1), while cagrillinide satisfaction hormone mimics amilin, so each prevents appetite through a separate passage. Their combined effects in non-ignition adults have not been tested in 3 tests; Therefore, further research is required.
About studies
Step 3A, multisaenter, random, double-blind, placebo- and active-controlled redistributed 1 test nominated 3,417 adults in 22 countries. Eligibility is required for body mass index (BMI) of 30 kg/m or more or at least one obesity related comradity and no diabetes, 27 kg/m or more BMI.
Participants were allocated for weekly injections of one of the four regimens in 21: 3: 3: 7: Fixed-dose Caglintide 2.4 mg plus semglutide 2.4 mg, semglutide, alone caglintide, or placebo. All volunteers also received standardized lifestyle coaching on diet and exercise.
The dose began at 0.25 mg of each active drug and increased by every four weeks until the full 2.4 mg dose reached the week 16. The dose was then maintained for 52 weeks, followed by seven weeks of observation. If intolerance developed (57.4% maintained the maximum dose at 68 week, the investigators stopped or stopped.
The DXA scan in a subgroup (7.4% participants) was used to track the changes in fat and lean tissue. Primary results were losing at least 5% of their fundamental weight in proportion to percentage of weight changes and in proportion to the participants, using the estimate analysis of treatment-policy (intention-to-treatment theory).
In confirmation secondary closing points and 20%,% 25%, and% 30% weight loss, all analyzes were performed on a treatment basis with an intense and 95% reported with confidence interval. Investigators also collected serial blood samples to track lipids, C-reactive proteins and change in liver enzymes, which provide a comprehensive picture of metabolic health. Retention strategies such as coaching calls, injection reminders and motivational interview kept the dropout rates low.
The safety signs of special interest, including pancreatitis, gallbladder events, neoplasm and suicidal ideas, were postponed by blind expert committees. An expansion phase (NCT06780449) will assess long -term results. Changes in the heart rate were monitored as part of the heart safety evaluation.
Study result
Of the 3,417 random adults, 2,108 received drug combinations, 302 received semaglutide, 302 received caglintide, and 705 received a placebo. The average age was 47 years old; Women included 67.6%, and most had dislipidemia or hypertension on the baseline. Till the week 68, the combination remained on 88.2% treatment assigned for therapy.
The combination produced average weight reduction of 20.4% under treatment policy estimate, with vs. 3.0% Placebo (-17.3% difference; p <0.001). In the test -upward estimated analysis (accounting for treatment of treatment), the cuts reached 22.7% and 2.3% respectively, with combination with therapy -21.6 kg to correspond to full weight loss of 21.6 kg.
In particular, 91.9% of the combination group lost at least 5% of the baseline weight, while 53.6% lost% 20%. In addition, 34.7% incurred a% 25% loss, and 19.3% gained 30% loss. In contrast, Semaglutide alone received 14.8% of patients to lose 25% weight, and alone had a yield of 6.5% in Caglintide.
BMI, waist circumference and waist-to-height ratio were greatly improved with combination therapy. Notable, 54% of people classified with obesity initially moved to the non-Mote BMI range by the end vs. 11.1% of the study with the placebo.
In the DXA subgroup (n = 252), the data showed that 67% of weight loss originated from fat mass and 33% lean soft tissue. This ratio of fat-to-decrease decrease in addition to installed obesity remedies and suggests that metabolic functions are preserved during weight loss. Fat mass declined by 17.0 kg with a combination compared to 3.4 kg with the placebo, while the absolute mass declined by 8.4 kg compared to 2.6 kg.
Cardiometabolic markers also transferred favorablely. Cystolic blood pressure fell by 3.2 mm Hg (-6.7 mm hg difference; p <0.001) with 9.9 mm HG and Placebo with a combination of 3.2 mm Hg. Among the Predibitic participants, 87.7% returned to Normoglycemia with a combination, compared to 32.2% on the placebo.
The quality of life and physical work, life-light clinical trials (IWQOL-Lite-C) and 36-utum short-form health survey (SF-36) revealed the impact of weight on the quality, more improvement with combination therapy. The combination of medical versus in other groups reduced the heart rate by 0.94 beats per minute.
Most of the adverse events were gastrointestinal, such as nausea, diarrhea, or constipation, and combination of 79.6% vs. 39.9% Placebo recipients of the hand. These incidents were usually light or moderate. Severe adverse incidents appeared in 9.8% of the combination group, including two deaths (one suicide, one cancer).
The disintegration was 5.9%less due to adverse incidents. The borders mainly included white and female participants, as well as general baseline metabolic values, reflecting improvements.
conclusion
In a nutshell, in short, as a result of adequate and clinically meaningful weight loss in adults with excessive weight or obesity with CODMINING with CODMINING CAGRILINTIDE and Semaglutide, monotherapy and placebo (- 5.5% vs. semglutide) better.
The combination also improved many cardiometabolic parameters, including blood pressure and glucose levels, and increased physical functioning. The body’s composition data should be carefully interpreted due to small subgroup analysis; However, the fat-to-romantic mass ratio aligns with metabolic protection goals.
While gastrointestinal side effects were common, they were mostly not intense. Minimum changes in heart rate indicate heart protection. This test highlights the ability to combine agents with supplementary mechanisms to deal with more effectively than obesity than single-dinner remedies.
